259 related articles for article (PubMed ID: 33106692)
1. Anaplastic Lymphoma Kinase Fusion: A Review of Therapeutic Drugs and Treatment Strategies.
Makimoto G; Ohashi K; Maeda Y; Kiura K
Acta Med Okayama; 2020 Oct; 74(5):371-379. PubMed ID: 33106692
[TBL] [Abstract][Full Text] [Related]
2. Treatment of advanced ALK-rearranged NSCLC following second-generation ALK-TKI failure.
Fukuda A; Yoshida T
Expert Rev Anticancer Ther; 2023; 23(11):1157-1167. PubMed ID: 37772744
[TBL] [Abstract][Full Text] [Related]
3. Successful Treatment with Crizotinib to Overcome Drug Resistance Possibly Due to Mesenchymal-epithelial Transition Amplification in a Lung Cancer Patient with the Echinoderm Microtubule-associated Protein-like 4-anaplastic Lymphoma Kinase Fusion Gene.
Shiraishi T; Yamasaki K; Kidogawa M; Shingu T; Ujimiya F; Jotatsu T; Matsumoto S; Izumi H; Nishida C; Goto K; Yatera K
Intern Med; 2023 Nov; 62(21):3215-3221. PubMed ID: 36927974
[TBL] [Abstract][Full Text] [Related]
4. Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism.
Xie B; Qiu Y; Zhou J; Du D; Ma H; Ji J; Zhu L; Zhang W
Clin Transl Oncol; 2022 Nov; 24(11):2231-2240. PubMed ID: 35852680
[TBL] [Abstract][Full Text] [Related]
5. Case report: Clinical complete response in advanced ALK-positive lung squamous cell carcinoma: a case study of successful anti-PD-1 immunotherapy post ALK-TKIs failure.
Yang C; Zeng R; Zha Y; Li Y; Wang T; Zhao R; Li M; Zhang J
Front Immunol; 2024; 15():1360671. PubMed ID: 38380327
[TBL] [Abstract][Full Text] [Related]
6. Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
Lingling X; Maoxi C; Wei Y; Jieting Z; Yuanyuan Y; Ning X
Lung Cancer; 2023 Dec; 186():107415. PubMed ID: 37907052
[TBL] [Abstract][Full Text] [Related]
7. EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries.
Elshatlawy M; Sampson J; Clarke K; Bayliss R
Mol Oncol; 2023 Jun; 17(6):950-963. PubMed ID: 37149843
[TBL] [Abstract][Full Text] [Related]
8. Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer.
Kauffmann-Guerrero D; Kahnert K; Huber RM
Drugs; 2021 Jan; 81(1):87-100. PubMed ID: 33226527
[TBL] [Abstract][Full Text] [Related]
9. [China expert recommendations on anaplastic lymphoma kinase-tyrosine kinase inhibitors treatment for advanced non-small cell lung cancer (2024 edition)].
;
Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):473-485. PubMed ID: 38317359
[TBL] [Abstract][Full Text] [Related]
10. ALK-rearrangement in non-small-cell lung cancer (NSCLC).
Du X; Shao Y; Qin HF; Tai YH; Gao HJ
Thorac Cancer; 2018 Apr; 9(4):423-430. PubMed ID: 29488330
[TBL] [Abstract][Full Text] [Related]
11. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound
Yoda S; Lin JJ; Lawrence MS; Burke BJ; Friboulet L; Langenbucher A; Dardaei L; Prutisto-Chang K; Dagogo-Jack I; Timofeevski S; Hubbeling H; Gainor JF; Ferris LA; Riley AK; Kattermann KE; Timonina D; Heist RS; Iafrate AJ; Benes CH; Lennerz JK; Mino-Kenudson M; Engelman JA; Johnson TW; Hata AN; Shaw AT
Cancer Discov; 2018 Jun; 8(6):714-729. PubMed ID: 29650534
[TBL] [Abstract][Full Text] [Related]
12. [A Case of Advanced Lung Squamous Cell Carcinoma with CLIP1-ALK Fusion Gene].
Yuan Y; Wang Z; Nie X; Zhang P; Li L
Zhongguo Fei Ai Za Zhi; 2022 Sep; 25(9):696-700. PubMed ID: 36172736
[TBL] [Abstract][Full Text] [Related]
13. Interstitial lung disease risk of anaplastic lymphoma kinase tyrosine kinase inhibitor treatment of non-small cell lung cancer: a real-world pharmacovigilance study.
Zhao M; Liu S; Xie R; Zhang J; Li J
Expert Opin Drug Saf; 2023; 22(12):1309-1316. PubMed ID: 37551674
[TBL] [Abstract][Full Text] [Related]
14. Alk-rearranged lung adenocarcinoma: From molecular genetics to therapeutic targeting.
Testa U; Castelli G; Pelosi E
Tumori; 2024 Apr; 110(2):88-95. PubMed ID: 37772924
[TBL] [Abstract][Full Text] [Related]
15. ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling.
Itchins M; Lau B; Hudson AL; Westman H; Xia CY; Hayes SA; Howell VM; Rodriguez M; Cooper WA; Wei H; Buckland M; Li BT; Li M; Rathi V; Fox SB; Gill AJ; Clarke SJ; Boyer MJ; Pavlakis N
Oncologist; 2020 Aug; 25(8):641-649. PubMed ID: 32558067
[TBL] [Abstract][Full Text] [Related]
16. Cardiac arrhythmias associated with anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
Wang F; Xu G; Wu X
Expert Opin Drug Saf; 2023; 22(11):1127-1132. PubMed ID: 37428255
[TBL] [Abstract][Full Text] [Related]
17. Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs.
Leporati R; Miliziano D; Beninato T; Mazzeo L; Manglaviti S; Brambilla M; Occhipinti M; Prelaj A; Proto C; Lo Russo G
Tumori; 2024 Apr; ():3008916241246659. PubMed ID: 38623748
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy.
Wang S; Hao X; Dai L; Lou N; Fan G; Gao R; Yang M; Xing P; Liu Y; Wang L; Zhang Z; Yao J; Tang L; Shi Y; Han X
Lung Cancer; 2024 Mar; 189():107503. PubMed ID: 38359741
[TBL] [Abstract][Full Text] [Related]
19. Ensartinib is effective in the treatment of advanced non-small-cell lung cancer with MET amplification after multi-line ALK-TKIs resistance: a case report.
Yang Y; He X; Xiao W; Bai J; Liu Y
Anticancer Drugs; 2024 Mar; 35(3):292-297. PubMed ID: 38179893
[TBL] [Abstract][Full Text] [Related]
20. LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion.
Mori S; Izumi H; Araki M; Liu J; Tanaka Y; Kagawa Y; Sagae Y; Ma B; Isaka Y; Sasakura Y; Kumagai S; Sakae Y; Tanaka K; Shibata Y; Udagawa H; Matsumoto S; Yoh K; Okuno Y; Goto K; Kobayashi SS
Commun Biol; 2024 Apr; 7(1):412. PubMed ID: 38575808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]